Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DuPont de Nemours
DD
|
+$1.55B |
| 2 |
Comcast
CMCSA
|
+$449M |
| 3 |
SLB Ltd
SLB
|
+$298M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$281M |
| 5 |
Qualcomm
QCOM
|
+$228M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$229M |
| 2 |
Sempra
SRE
|
+$192M |
| 3 |
Bausch Health
BHC
|
+$183M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$175M |
| 5 |
PepsiCo
PEP
|
+$173M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 12.58% |
| 2 | Energy | 11.62% |
| 3 | Consumer Discretionary | 8.89% |
| 4 | Financials | 8.63% |
| 5 | Technology | 8.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Pacira BioSciences
PCRX
$991M
| $21M | 0.04% |
511,099
-34,471
| -6% | -$2.11M |
|
552
TETRA Technologies
TTI
$1B
| $21M | 0.04% |
3,547,439
+1,699,638
| +92% | +$10.8M |
|
553
Kirby Corp
KEX
$7.32B
| $20.9M | 0.04% |
338,034
+160,459
| +90% | +$11.3M |
|
|
TCF
554
DELISTED
TCF Financial Corporation Common Stock
TCF
| $20.7M | 0.04% |
641,046
+136,616
| +27% | +$4.43M |
|
555
Broadridge
BR
$21.1B
| $20.7M | 0.04% |
373,409
+91,555
| +32% | +$4.92M |
|
556
Bread Financial
BFH
$4.04B
| $20.6M | 0.04% |
+99,474
| New | +$21.5M |
|
557
Charles River Laboratories
CRL
$14.3B
| $20.4M | 0.04% |
320,442
+108,867
| +51% | +$7.82M |
|
|
ARMH
558
DELISTED
ARM HOLDINGS PLC ADS
ARMH
| $20.3M | 0.04% |
469,627
-46,535
| -9% | -$2.08M |
|
559
Vanda Pharmaceuticals
VNDA
$322M
| $20.3M | 0.04% |
1,795,468
+711,709
| +66% | +$8.71M |
|
560
Smith & Wesson
SWBI
$612M
| $20.2M | 0.04% |
1,557,849
+1,046,905
| +205% | +$13.7M |
|
561
PUT
Vale
VALE
$64B
| $20.2M | 0.04% |
4,808,000
| – | – |
|
562
lululemon athletica
LULU
$13.9B
| $20.1M | 0.04% |
396,537
+48,179
| +14% | +$2.94M |
|
|
GTLS
563
DELISTED
Chart Industries
GTLS
| $20M | 0.04% |
1,041,520
+202,794
| +24% | +$5.35M |
|
564
First Horizon
FHN
$11.6B
| $20M | 0.04% |
1,408,265
-407,656
| -22% | -$6.16M |
|
565
Energy Transfer Partners
ET
$72.6B
| $19.9M | 0.04% |
958,342
-592,000
| -38% | -$16.7M |
|
566
CALL
Neurocrine Biosciences
NBIX
$15.6B
| $19.9M | 0.04% |
500,000
+200,000
| +67% | +$9.67M |
|
|
ITCI
567
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $19.8M | 0.04% |
494,812
+1,768
| +0.4% | +$57.7K |
|
568
Moody's
MCO
$88.6B
| $19.8M | 0.04% |
201,496
+186,926
| +1,283% | +$19.9M |
|
|
OUTR
569
DELISTED
OUTERWALL INC
OUTR
| $19.8M | 0.04% |
347,397
+59,864
| +21% | +$4.11M |
|
570
Fortinet
FTNT
$112B
| $19.7M | 0.04% |
+2,322,595
| New | +$20.6M |
|
571
Empire State Realty Trust
ESRT
$819M
| $19.7M | 0.04% |
1,157,920
+1,036,214
| +851% | +$17.8M |
|
|
DRII
572
DELISTED
DIAMOND RESORTS INTL, INC
DRII
| $19.7M | 0.04% |
842,291
+205,733
| +32% | +$5.67M |
|
|
JCP
573
DELISTED
J.C. Penney Company, Inc.
JCP
| $19.7M | 0.04% |
+2,117,815
| New | +$18.8M |
|
574
D.R. Horton
DHI
$41.7B
| $19.7M | 0.04% |
669,323
-549,341
| -45% | -$16.2M |
|
575
AstraZeneca
AZN
$259B
| $19.6M | 0.04% |
308,558
-68,663
| -18% | -$4.52M |
|
Similar funds
Israel Englander's Q3 2015 Portfolio in Review
As of Q3 2015, Israel Englander held 4,098 positions worth $51.6B, down 2.3% from $52.9B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Israel Englander deployed $5.12B of net new capital in Q3 2015, opening 839 new positions and adding to 1,320 existing holdings. Its largest new stake was BP: 4,551,492 shares worth $117M.
By sector, the portfolio is most concentrated in Healthcare at 13% of assets, down from 15% a quarter earlier, followed by Energy and Consumer Discretionary.
On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $229M trimmed.
- Israel Englander's largest Q3 2015 buy was BP: 4,551,492 shares worth $117M.
- Israel Englander added most to DuPont de Nemours in Q3 2015, an estimated $1.55B increase.
- Israel Englander's biggest Q3 2015 reduction was Alexion Pharmaceuticals, cutting an estimated $229M.
- Israel Englander fully exited PepsiCo in Q3 2015, selling an estimated $173M.
- Israel Englander's ten largest holdings make up 14% of its $51.6B portfolio in Q3 2015.
- Israel Englander opened 839 new positions and closed 681 in Q3 2015.
- Israel Englander's portfolio value fell 2.3% quarter-over-quarter to $51.6B.
Based on Millennium Management's 13F filing for Q3 2015, filed 16 Nov 2015.